Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02262611

Enrollment

266

Registered

2014-10-13

Start date

2003-01-31

Completion date

Unknown

Last updated

2014-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

Study to obtain long-term data on effects, safety and tolerability in routine medical practice and to investigate the potential of telmisartan to prevent secondary organ damage

Interventions

DRUGMicardis®

DRUGMicardisPlus®

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients of both gender aged \>=18 admitted to a hospital due to insufficiently controlled essential hypertension. No additional selection criteria have to be considered. Treatment was at the discretion of the physician following the summary of product information for Micardis® and MicardisPlus®

Exclusion criteria

* not applicable

Design outcomes

Primary

Measure	Time frame
Number of patients with abnormal changes in laboratory parameters	up to 1 year
Change in systolic blood pressure	up to 1 year
Change in diastolic blood pressure	up to 1 year
Number of patients with adverse events	up to 1 year
Number of patients with clinically significant changes in vital signs	up to 1 year

Secondary

Measure	Time frame
Global assessment of tolerability by investigator on a 4-point scale	2 weeks, after 1 year
Global assessment of efficacy by investigator on a 4-point scale	2 weeks, after 1 year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026